SCHEMBL2904811

SCHEMBL2904811

[CH]=Cc1ccc(N2CCOCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.56
MAPT P10636 12/20 0.56
KDM4E B2RXH2 7/20 0.56
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
NPC1 O15118 5/20 0.56
RAB9A P51151 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
MITF O75030 1/20 0.54
LMNA P02545 3/20 0.54
HTT P42858 3/20 0.53
CYP1A2 P05177 1/20 0.53
HPGD P15428 5/20 0.53
HSD17B10 Q99714 4/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 2/20 0.52
USP2 O75604 1/20 0.52
MAPK1 P28482 1/20 0.52
GAA P10253 2/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9915631 0.84 MAPT (0.73) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL27640792 0.84 TRIM24 (0.63) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL9093746 0.83 LMNA (0.71) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2905292 0.83 ALDH1A1 (0.64) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2904812 0.81 ALDH1A1 (0.54) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL4419960 0.81 ALDH1A1 (0.59) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL211336 0.81 TRIM24 (0.70) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL12526120 0.79 TRIM24 (0.68) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL881493 0.79 TRIM24 (0.68) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL22198154 0.79 ALDH1A1 (0.67) ALDH1A1MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
CN-103635470-B Chromene compounds and solidification compound 株式会社德山 2016-12-21 CN disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2725017-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2016-06-29 EP disclosed
CN-103517899-B Chromene compounds 株式会社德山 2016-06-15 CN disclosed
EP-2669277-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-07-01 EP disclosed
EP-2684886-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-06-03 EP disclosed
EP-2669278-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-05-27 EP disclosed
CN-102812104-B Photochromic curable composition TOKUYAMA CORP 2015-05-13 CN disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
CN-1333770-A Novel Bicyclic Compounds BASLIER PHARMACEUTICAL AG (CH) 2002-01-30 CN disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 ALDH1A1 2905/4885MAPT 1285/4885KDM4E 985/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 ALDH1A1 3101/4885MAPT 1368/4885KDM4E 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.